XML 34 R14.htm IDEA: XBRL DOCUMENT v3.6.0.2
Financial Instruments and Derivative Financial Instruments (Notes)
 12 Months Ended
Dec. 31, 2016
Derivative [Line Items]  
Derivative Instruments and Hedging Activities Disclosure [Text Block]
Financial Instruments and Derivative Financial Instruments
Concentrations of Credit Risks:  The Company sells its products to gas producers, distributors and end-users across the industrial gas, hydrocarbon, chemical processing, respiratory therapy, and life sciences industries in countries all over the world. Approximately 50%, 51%, and 53% of sales were to customers in foreign countries in 2016, 2015, and 2014, respectively. One customer exceeded ten percent of consolidated sales in 2016. Total sales revenue from this customer represents approximately $98,919 of total consolidated sales revenue and is attributable to the E&C, D&S, and BioMedical segments. No single customer exceeded ten percent of consolidated sales in 2015 and 2014. Sales to the Company’s top ten customers accounted for 38%, 36% and 34% of consolidated sales in 2016, 2015, and 2014, respectively. The Company’s sales to particular customers fluctuate from period to period, but the large industrial gas producer and distributor customers of the Company tend to be a consistently large source of revenue for the Company.
The Company is also subject to concentrations of credit risk with respect to its cash and cash equivalents and forward foreign currency exchange contracts. To minimize credit risk from these financial instruments, the Company enters into arrangements with major banks and other quality financial institutions and invests only in high-quality instruments. The Company does not expect any counterparties to fail to meet their obligations.
The changes in fair value with respect to the Company’s foreign currency forward contracts generated a net loss of $765 for the year ended December 31, 2016 and net gains of $2,673 and $2,670 for the years ended December 31, 2015 and 2014, respectively.